Advances in the Classification of Myeloid and Lymphoid Neoplasms

Arber, Daniel A.; Campo, Elı́as; Jaffe, Elaine S.

doi:10.1007/s00428-022-03487-1

Cited by 13 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 For example, BPDCN is classified separately from the group of histiocytic/dendritic cell neoplasms in the International Consensus Classification. 8 Yet it is classified within the group of histiocytic/dendritic cell neoplasms in the latest WHO classification 2 ; therefore, we considered BPDCN as a histiocytosis subtype and included it in our study. HS and IDCS are histologic variants of MH 1 ; therefore, they were grouped together with MH.…”

Section: Methodsmentioning

confidence: 99%

Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms

Kemps,

Kester,

Scheijde‐Vermeulen

et al. 2024

Histopathology

View full text Add to dashboard Cite

AimsThe discovery of somatic genetic alterations established many histiocytic disorders as haematologic neoplasms. We aimed to investigate the demographic characteristics and additional haematologic cancers of patients diagnosed with histiocytic disorders in The Netherlands.Methods and resultsWe retrieved data on histiocytosis patients from the Dutch Nationwide Pathology Databank (Palga). During 1993 to 2022, more than 4000 patients with a pathologist‐assigned diagnosis of a histiocytic disorder were registered in Palga. Xanthogranulomas were the most common subtype, challenging the prevailing assumption that Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder. LCH and juvenile xanthogranuloma (JXG) had a peak incidence in the first years of life; males were overrepresented among all histiocytosis subgroups. 118 patients had a histiocytic disorder and an additional haematologic malignancy, including 107 (91%) adults at the time of histiocytosis diagnosis. In 16/118 patients, both entities had been analysed for the same genetic alteration(s). In 11 of these 16 patients, identical genetic alterations had been detected in both haematologic neoplasms. This included two patients with PAX5 p.P80R mutated B cell acute lymphoblastic leukaemia and secondary histiocytic sarcoma, further supporting that PAX5 alterations may predispose (precursor) B cells to differentiate into the myeloid lineage. All 4/11 patients with myeloid neoplasms as their additional haematologic malignancy had shared N/KRAS mutations.ConclusionsThis population‐based study highlights the frequency of xanthogranulomas. Furthermore, our data add to the growing evidence supporting clonal relationships between histiocytic/dendritic cell neoplasms and additional myeloid or lymphoid malignancies. Particularly adult histiocytosis patients should be carefully evaluated for the development of these associated haematologic cancers.

show abstract

Section: Methodsmentioning

confidence: 99%

Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms

Kemps,

Kester,

Scheijde‐Vermeulen

et al. 2024

Histopathology

View full text Add to dashboard Cite

show abstract

“…Chronic myeloid leukemia (CML) belongs to the group of myeloproliferative neoplasms (MPN) ( 1 ). The incidence of CML is 1–2 cases per 100,000 adults, and men are affected slightly more often than women ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

Hollenbach,

Rogahn,

le Coutre

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTyrosine kinase inhibitors (TKIs) have significantly lowered mortality of chronic myeloid leukemia (CML) patients adjusting life expectancy to that of the standard population. However, CML and its treatment with TKIs causes a high disease burden. Physical exercise (PE) could be a non-pharmacological approach to reducing these and improving quality of life.PurposeThe aim of this study was to determine the individual disease burden as well as PE preferences of CML patients and to deduce thereof specific PE recommendations.MethodsThis multicenter survey was conducted in cooperation with the LeukaNET/Leukemia-patient network including CML patients aged ≥18 years (German Registry of Clinical Trials, DRKS00023698). The severity of selected symptoms was assessed using the adapted Myeloproliferative Neoplasms Symptom Assessment Form: 0 (absent), 1–30 (mild), 31–70 (moderate), or 71–100 (severe). Information about patients’ PE needs and preferences depending on their motivation was recorded.ResultsA total of 212 questionnaires were analyzed (52% female, median age 54 years). The prevalence of moderate-to-severe symptoms was 49% for fatigue, 40% for musculoskeletal pain, and 37% for concentration problems. Other commonly reported symptoms included skin reactions (42%) and weight gain (24%). The proportion of overweight/obese patients was 52%. Half of all respondents requested more information regarding PE. Patients with CML preferred individual training (82%), located outdoors (71%), at home (47%), or in an indoor swimming pool (31%). Regarding the training frequency, sports-inactive patients preferred a frequency of 1–2 training sessions per week, whereas sports-active patients preferred 3–4 sessions per week (p <0.001). Sports-inactive patients preferred a training time of 15–45 minutes, while sports-active patients preferred 30–60 minutes (p = 0.002). Subsequently, PE recommendations were developed for patients with CML. Combined resistance and endurance training (moderate intensity twice per week for 30 minutes) was recommended for beginners. Obese patients should prioritize joint-relieving sports. To reduce the risk of skin reactions, direct sunlight and possibly water sports should be avoided, and UV protection should be used.ConclusionCounseling and motivation of CML patients to be physically active should be part of the standard of care as well as support for implementation.

show abstract

“…This resulted in special reports in Blood in 2022 and 2023 describing the International Consensus Classification (ICC) of myeloid neoplasms, acute leukemias, and mature lymphoid neoplasms, [3][4][5] and a monographic issue of Virchows Archives in January 2023. 6 Under the guidance of the EHA board and with the input of experts in the field, two documents were prepared to shed light on the differences between the new classifications. One document describes the updates to the classification of mature lymphoid neoplasms (File S1), while the second document describes the updates to the classification of myeloid neoplasms and acute leukemias (File S2).…”

mentioning

confidence: 99%

“…To address this, a CAC endorsed by SH and EAHP, comprising an international group of pathologists, clinicians, and scientists separate from the WHO, was convened to update the WHO 2017 classification. This resulted in special reports in Blood in 2022 and 2023 describing the International Consensus Classification (ICC) of myeloid neoplasms, acute leukemias, and mature lymphoid neoplasms, 3–5 and a monographic issue of Virchows Archives in January 2023 6 …”

mentioning

confidence: 99%

See 1 more Smart Citation

Precision hematology: Navigating the evolution of diagnostic classifications in the era of globalized medicine

Macintyre,

Döhner,

Grønbæk

et al. 2024

HemaSphere

View full text Add to dashboard Cite

Advances in the Classification of Myeloid and Lymphoid Neoplasms

Cited by 13 publications

References 23 publications

Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms

Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms

Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

Precision hematology: Navigating the evolution of diagnostic classifications in the era of globalized medicine

Contact Info

Product

Resources

About